22 December 2022 : Database Analysis
Impact of the De Ritis Ratio on the Prognosis of Patients with Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention
Kai Wang
1ABCE, Zijun Chen1ABE, Deli Zeng1BF, Maojuan Ran1AEFG*
DOI: 10.12659/MSM.937737
Med Sci Monit 2022; 28:e937737
Table 1 Clinical data of the study population.
| Overall population | Low De Ritis ratio (n=177) | High De Ritis ratio (n=27) | p value | |
|---|---|---|---|---|
| Age (years), n (%) | <0.001 | |||
| <60 | 22 (10.8) | 21 (11.9) | 1 (3.7) | |
| 60–69 | 58 (28.4) | 56 (31.6) | 2 (7.4) | |
| 70–79 | 71 (34.8) | 61 (34.5) | 10 (37.0) | |
| ≥80 | 53 (26.0) | 39 (22.0) | 14 (51.9) | |
| Men, n (%) | 142 (69.6) | 127 (71.8) | 15 (55.6) | 0.139 |
| BMI (kg/m), n (%) | 0.002 | |||
| <18.5 | 17 (8.3) | 13 (7.3) | 4 (14.8) | |
| 18.5–24.9 | 119 (58.3) | 98 (55.4) | 21 (77.8) | |
| ≥25.0 | 68 (33.3) | 66 (37.3) | 2 (7.4) | |
| Alb (g/dL) ≥4.0, n (%) | 115 (56.4) | 106 (59.9) | 9 (33.3) | 0.017 |
| Hb (g/dL) (mean (SD)) | 13.58 (2.01) | 13.80 (1.92) | 12.14 (2.02) | <0.001 |
| eGFR(mL/min/1.73 m) (mean [SD]) | 61.32 (24.61) | 64.09 (23.42) | 43.15 (24.92) | <0.001 |
| CRP (mg/dL), n (%) | 0.964 | |||
| 0.01–0.03 | 34 (16.7) | 30 (16.9) | 4 (14.8) | |
| 0.04–0.11 | 64 (31.4) | 55 (31.1) | 9 (33.3) | |
| 0.12–0.33 | 55 (27.0) | 47 (26.6) | 8 (29.6) | |
| 0.34–9.20 | 51 (25.0) | 45 (25.4) | 6 (22.2) | |
| AST (mean (SD)) | 24.66 (10.93) | 24.58 (11.02) | 25.22 (10.52) | 0.776 |
| ALT (mean (SD)) | 20.90 (12.19) | 22.42 (12.24) | 10.93 (5.17) | <0.001 |
| LVEF (mean (SD)) | 63.36 (9.88) | 63.51 (9.59) | 62.33 (11.81) | 0.564 |
| OCI, n (%) | 35 (17.2) | 28 (15.8) | 7 (25.9) | 0.306 |
| PAD, n (%) | 53 (26.0) | 45 (25.4) | 8 (29.6) | 0.819 |
| Hypertension, n (%) | 151 (74.0) | 132 (74.6) | 19 (70.4) | 0.819 |
| Diabetes mellitus, n (%) | 73 (35.8) | 65 (36.7) | 8 (29.6) | 0.617 |
| Smoker, n (%) | 101 (49.5) | 94 (53.1) | 7 (25.9) | 0.015 |
| Aspirin, n (%) | 202 (99.0) | 176 (99.4) | 26 (96.3) | 0.622 |
| Thienopiridines, n (%) | 200 (98.0) | 174 (98.3) | 26 (96.3) | 1.000 |
| Warfarin, n (%) | 5 (2.5) | 3 (1.7) | 2 (7.4) | 0.263 |
| DOAC, n (%) | 21 (10.3) | 18 (10.2) | 3 (11.1) | 1.000 |
| Statins, n (%) | 111 (54.4) | 101 (57.1) | 10 (37.0) | 0.082 |
| ACEI/ARB, n (%) | 106 (52.0) | 90 (50.8) | 16 (59.3) | 0.543 |
| βblocker, n (%) | 55 (27.0) | 46 (26.0) | 9 (33.3) | 0.57 |
| MRA, n (%) | 11 (5.4) | 10 (5.6) | 1 (3.7) | 1.000 |
| Bifurcation lesions, n (%) | 101 (49.5) | 85 (48.0) | 16 (59.3) | 0.378 |
| Multivessel lesions, n (%) | 53 (26.0) | 47 (26.6) | 6 (22.2) | 0.808 |
| LMT, n (%) | 13 (6.4) | 12 (6.8) | 1 (3.7) | 0.852 |
| Calcification lesions, n (%) | 29 (14.2) | 23 (13.0) | 6 (22.2) | 0.326 |
| CTO, n (%) | 12 (5.9) | 12 (6.8) | 0 (0.0) | 0.339 |
| BMI – body mass index; Alb – serum albumin; Hb – hemoglobin; eGFR – estimated glomerular filtration rate; CRP – C-reactive protein; LVEF – left ventricular ejection fraction; OCI – old cerebral infarction; PAD – peripheral artery disease; DOAC – direct oral anticoagulant; MRA – mineralocorticoid receptor antagonists; LMT – left main trunk; CTO – chronic total occlusion. | ||||